Examkin

Question

Difficulty: HardPharmacologic Interventions

A 41-year-old woman is evaluated in the oncology clinic to discuss adjuvant endocrine therapy for breast cancer. She recently underwent a lumpectomy and sentinel lymph node biopsy for a stage I, estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative invasive ductal carcinoma. Radiation therapy was completed two weeks ago. Her medical history is significant for major depressive disorder, which has been well controlled on fluoxetine for the past four years. She also reports experiencing new-onset, disruptive hot flashes that disturb her sleep. Her menstrual cycles are regular, occurring every 2828 days. Her body mass index is 24 kg/m224 \text{ kg/m}^2. Vital signs and physical examination are within normal limits. The oncologist plans to initiate tamoxifen. Which of the following is the most appropriate pharmacologic adjustment for this patient?

  1. A
    Continue fluoxetine and initiate tamoxifen
  2. B
    Switch fluoxetine to bupropion and initiate tamoxifen
  3. C
    Switch fluoxetine to paroxetine and initiate tamoxifen
  4. Switch fluoxetine to venlafaxine and initiate tamoxifenAnswer
  5. E
    Maintain fluoxetine and initiate anastrozole instead of tamoxifen

Answer

The most appropriate adjustment is to switch fluoxetine to venlafaxine and initiate tamoxifen.
The correct answer involves substituting the patient's current antidepressant with one that does not inhibit the CYP2D6 enzyme while also treating her vasomotor symptoms. Tamoxifen is a selective estrogen receptor modulator (SERM) used for adjuvant therapy in hormone receptor-positive breast cancer. It is a prodrug that requires hepatic conversion by the cytochrome P450 2D6 (CYP2D6) enzyme into its highly active metabolite, endoxifen. Fluoxetine is a potent CYP2D6 inhibitor. If fluoxetine is continued, it will prevent the formation of endoxifen, drastically reducing the efficacy of the breast cancer treatment and increasing the risk of recurrence. To manage the patient's major depressive disorder and newly onset hot flashes (a common side effect of tamoxifen and declining estrogen), an alternative antidepressant with minimal CYP2D6 inhibition is required. Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), is highly effective for both depression and hot flashes and does not significantly inhibit CYP2D6, making it the safest and most appropriate choice.

Step-by-Step Solution

1
Evaluate the patient's menopausal status and breast cancer receptor profile.
The patient is premenopausal (regular 2828-day cycles) with estrogen receptor-positive breast cancer.
This confirms that tamoxifen is the standard-of-care adjuvant endocrine therapy, as aromatase inhibitor monotherapy is contraindicated in premenopausal women.
2
Assess the pharmacokinetic properties of the intended therapy (tamoxifen).
Tamoxifen is a prodrug that must be converted to its highly active metabolites, primarily endoxifen, via the hepatic cytochrome P450 2D6 (CYP2D6) enzyme.
Understanding the activation pathway is required to identify potential drug-drug interactions that could compromise cancer treatment efficacy.
3
Review the patient's current medication list for potential CYP2D6 interactions.
The patient is taking fluoxetine, which is a potent inhibitor of the CYP2D6 enzyme.
Concurrent use of fluoxetine and tamoxifen significantly reduces the plasma concentration of endoxifen, increasing the risk of breast cancer recurrence. Fluoxetine must be discontinued.
4
Select a safe and effective alternative for the patient's comorbid conditions.
Venlafaxine is selected as the alternative agent.
Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), effectively treats both major depressive disorder and vasomotor symptoms (hot flashes) while exhibiting minimal to no CYP2D6 inhibition.

Key Concept

Tamoxifen is a prodrug requiring CYP2D6 activation; concurrent use of strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, bupropion) is contraindicated and requires switching to a non-inhibiting alternative like venlafaxine.
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic